Print Page  Close Window

SEC Filings

SC 14D9/A
VITAE PHARMACEUTICALS, INC filed this Form SC 14D9/A on 10/17/2016
Entire Document
 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

SCHEDULE 14D-9

(Rule 14d-101)

 

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

(Amendment No. 2)

 


 

Vitae Pharmaceuticals, Inc.

(Name of Subject Company)

 


 

Vitae Pharmaceuticals, Inc.

(Name of Persons Filing Statement)

 


 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

92847N103

(CUSIP Number of Class of Securities)

 

Jeffrey S. Hatfield

President and Chief Executive Officer

502 West Office Center Drive

Fort Washington, PA 19034

(215) 461-2000

(Name, address, and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)

 

Copies to:

 

Jay K. Hachigian

 

Scott Applebaum

Gregg A. Griner

 

General Counsel and Corporate Secretary

Andrew Y. Luh

 

Vitae Pharmaceuticals, Inc.

Keith J. Scherer

 

502 West Office Center Drive

Albert W. Vanderlaan

 

Fort Washington, PA 19034

Gunderson Dettmer Stough

 

(215) 461-2000

Villeneuve Franklin & Hachigian, LLP

 

 

One Marina Park Drive, Suite 900

 

 

Boston, MA 02210

 

 

(617) 648-9100

 

 

 


 

o              Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.